Karolinska Development Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Karolinska Development (STO:KDEV) Full Year 2024 Results

Key Financial Results

• Net loss: kr8.10m (down by 250% from kr5.39m profit in FY 2023).
• kr0.03 loss per share (down from kr0.02 profit in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Karolinska Development EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 8.1%. Earnings per share (EPS) exceeded analyst estimates by 67%.

Looking ahead, revenue is forecast to grow 4.2% p.a. on average during the next 2 years, compared to a 26% growth forecast for the Pharmaceuticals industry in Sweden.

Performance of the Swedish Pharmaceuticals industry.

The company's shares are down 5.0% from a week ago.

Risk Analysis

Be aware that Karolinska Development is showing 4 warning signs in our investment analysis and 2 of those are potentially serious...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.